A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler

Annals of Allergy, Asthma and Immunology

Volumn 86, Issue 1, 2001, Pages 19-27

  Bensch, George ^a   Lapidus, Robert J ^b   Levine, Bernard E ^c   Lumry, William ^d   Yegen, Ümit ^e   Kiselev, Pavel ^e   DellaCioppa, Giovanni ^f  

^a Allergy Immunology and Asthma Group   (United States)

^b Rocky Mountain Pulmonary Medicine   (United States)

^c Pulmonary Associates   (United States)

^d Novartis Pharmaceuticals Corporation ^*

^e NOVARTIS PHARMA AG   (Switzerland)

^f Horsham Research Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FORMOTEROL; FORMOTEROL FUMARATE; PLACEBO; SALBUTAMOL;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; SCHOOL CHILD;

EID: 0035132642     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62351-4     Document Type: Article

References (24)

1. 2-adrenoceptor agonist: Acute studies of selectivity and duration of effect after inhaled and oral administration
2. Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus
3. Pharmacologic characterization of formoterol in comparison with isoprenaline, fenoterol and salbutamol in tracheal muscle strips and lung membranes of the guinea pig
4. Salmeterol, formoterol, and salbutamol in the isolated guinea pig trachea: Differences in maximum relaxant effect and potency but not in functional antagonism
5. 2-adrenoceptor agonist formoterol
6. Evaluation of a new bronchodilator, formoterol, using biochemical parameters
7. 3H]formoterol binding sites in lung: Characterization and autoradiographic mapping
8. Rapid onset of action of inhaled formoterol in asthmatic patients
9. Salmeterol versus formoterol in patients with moderately severe asthma: Onset and duration of action
10. Long-acting inhaled beta agonists
11. Dose-response of inhaled drugs in asthma: An update
12. The duration of action of inhaled formoterol dry powder
13. The first 20 minutes after a single dose of inhaled salmeterol in asthmatic children
14. 2-agonists: Implications for drug therapy
15. Bronchodilator therapy in the management of acute asthma
16. Evaluation of conventional press-and-breathe metered-dose inhaler technique in 501 patients
17. Assessing the use of metered dose inhalers by adults with asthma
18. Inhaled therapy in asthma: Metered-dose inhaler experience
19. Effects of instruction by practice assistants on inhaler technique and respiratory symptoms of patients: A controlled randomized videotaped intervention study
20. 2-adrenergic receptor agonist: Double-blind comparison with salbutamol and placebo in children with asthma
21. Regular formoterol treatment in mild asthma: Effect on bronchial responsiveness during and after treatment
22. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma
23. Current therapies for asthma: Promise and limitations